<?xml version="1.0" encoding="UTF-8"?>
<p>Clone 13 vaccinated animals can be easily differentiated from naturally infected animals using DIVA test, as the immunized animals do not elicit antibodies against the deleted antigen (NSs). The mutant virus is unable to replicate efficiently in vaccinated animals and does not produce a long-term immune response, which is the main disadvantages of the vaccine. The Clone 13 vaccine has been licensed in some countries, including South Africa, Kenya, Botswana and Namibia [
 <xref rid="B73-viruses-11-00139" ref-type="bibr">73</xref>]. Furthermore, CL13T, a thermostable clonal isolate of Clone 13 has been developed. This vaccine was safe and immunogenic in sheep, cattle, goats and pregnant camels [
 <xref rid="B90-viruses-11-00139" ref-type="bibr">90</xref>,
 <xref rid="B91-viruses-11-00139" ref-type="bibr">91</xref>].
</p>
